Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
University of Wisconsin-Madison
mi
from
Madison, WI
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
University of Wisconsin-Madison
mi
from
Madison, WI
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
David Geffen School of Medicine, UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Hospital
mi
from
Orlando, FL
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Washington Unviersity School of Medicine
mi
from
Saint Louis, MO
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Washington Unviersity School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
Duke University
mi
from
Durham, NC
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated:  12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1
Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients With Spinal Muscular Atrophy Type 1 With One or Two SMN2 Copies Delivering AVXS-101 by Intravenous Infusion
Status: Enrolling
Updated: 12/31/1969
University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage Huntington's Disease
Status: Enrolling
Updated:  12/31/1969
Columbia University
mi
from
New York, NY
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage HD
Feasibility and Acceptability of Implementing a Clinic-based Physical Activity Coaching Intervention in People With Premanifest and Early Stage Huntington's Disease
Status: Enrolling
Updated: 12/31/1969
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Barrow Neurology Clinics
mi
from
Phoenix, AZ
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Barrow Neurology Clinics
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Northwest NeuroSpecialists, PLLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of California-Davis
mi
from
Sacramento, CA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Kaiser Permanente Neurology
mi
from
San Diego, CA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Kaiser Permanente Neurology
mi
from
San Diego, CA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Advanced Neurology of Colorado
mi
from
Fort Collins, CO
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Advanced Neurology of Colorado
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
The MS Treatment Center at Griffin Hospital
mi
from
Derby, CT
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
The MS Treatment Center at Griffin Hospital
mi
from
Derby, CT
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Associated Neurologists of Southern Connecticut, PC
mi
from
Fairfield, CT
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Neurological Center of South Florida
mi
from
Miami, FL
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Neurological Center of South Florida
mi
from
Miami, FL
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Harbourside Medical Plaza
mi
from
Tampa, FL
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Harbourside Medical Plaza
mi
from
Tampa, FL
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Shepherd Center
mi
from
Atlanta, GA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Shepherd Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
The University of Chicago Hospitals
mi
from
Chicago, IL
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
The University of Chicago Hospitals
mi
from
Chicago, IL
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Consultants in Neurology, Ltd.
mi
from
Northbrook, IL
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Fort Wayne Neurological Center
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Maryland MD Center for MS
mi
from
Baltimore, MD
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Maryland MD Center for MS
mi
from
Baltimore, MD
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Wayne State University
mi
from
Detroit, MI
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Henry Ford Hospital Dept of Neurology
mi
from
Detroit, MI
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Henry Ford Hospital Dept of Neurology
mi
from
Detroit, MI
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Minneapolis Clinic of Neurology
mi
from
Golden Valley, MN
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
University of Minnesota Medical School, Dept of Neurology
mi
from
Minneapolis, MN
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
University of Minnesota Medical School, Dept of Neurology
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Nevada Neurological Consultants
mi
from
Henderson, NV
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Nevada Neurological Consultants
mi
from
Henderson, NV
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Albany Medical College Dept of Neurology MC-70
mi
from
Albany, NY
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Albany Medical College Dept of Neurology MC-70
mi
from
Albany, NY
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Neurology University of Rochester
mi
from
Rochester, NY
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Neurology University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
SUNY At Stony Brook U Hospital - Department of Neurology
mi
from
Stony Brook, NY
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
SUNY At Stony Brook U Hospital - Department of Neurology
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
SUNY Upstate Medical University Dept of Neurology
mi
from
Syracuse, NY
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
SUNY Upstate Medical University Dept of Neurology
mi
from
Syracuse, NY
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
MS Center/CHS
mi
from
Charlotte, NC
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
MS Center/CHS
mi
from
Charlotte, NC
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Oak Clinic for Multiple Sclerosis
mi
from
Uniontown, OH
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Oak Clinic for Multiple Sclerosis
mi
from
Uniontown, OH
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Medford Neurological and Spine Clinic
mi
from
Medford, OR
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Medford Neurological and Spine Clinic
mi
from
Medford, OR
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Physicians Dept of Neurology
mi
from
Philadelphia, PA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Physicians Dept of Neurology
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Baptist West Hospital
mi
from
Knoxville, TN
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Baptist West Hospital
mi
from
Knoxville, TN
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
The University of Texas, Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Central Texas Neurology
mi
from
Round Rock, TX
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Central Texas Neurology
mi
from
Round Rock, TX
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Neurology Health Care Service / Fletcher Allen Health Care
mi
from
Burlington, VT
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Neurology Health Care Service / Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Neurology Center of Fairfax
mi
from
Fairfax, VA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Neurology Center of Fairfax
mi
from
Fairfax, VA
Click here to add this to my saved trials
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated:  12/31/1969
Blue Ridge Research Center
mi
from
Roanoke, VA
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Phase IV, Multicenter, Open Label, Randomized Study of Rebif® 44 mcg Administered Three Times Per Week by Subcutaneous Injection Compared With Copaxone® 20 mg Administered Daily by Subcutaneous Injection in the Treatment of Relapsing Remitting Multiple Sclerosis
Status: Enrolling
Updated: 12/31/1969
Blue Ridge Research Center
mi
from
Roanoke, VA
Click here to add this to my saved trials